What Sangamo Therapeutics UK say about themselves
“Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation.”
“Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation.”
Officer details are public data from the Companies House register.
People and entities with significant control, from the Companies House PSC register
Balance sheet as at 31 December 2024 · small accounts
| 2024 | |
|---|---|
| Current Assets | £2,461,458 |
| Debtors | £2,083,492 |
| Cash | £377,966 |
| Creditors (< 1 year) | £392,811 |
| Net Current Assets | £2,068,647 |
| Shareholder Funds | £2,068,647 |
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 13 May 2026 | Accounts for a small company | 31 December 2024 | ||
| 5 May 2026 | Confirmation statement with updates | 21 April 2026 | ||
| 13 April 2026 | Appointment of a director | |||
| 13 April 2026 | Termination of appointment of a director | |||
| 15 May 2025 | Accounts for a small company | 31 December 2023 |
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →